Calcium Channel Blocker Drugs Market
- 2026 年市場規模
- USD 17,460.6 Mn
- 2033 年預估規模
- USD 24,857.4 Mn
- 年複合成長率 CAGR
- 5.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Calcium Channel Blocker Drugs Market, By Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), By Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.
Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease – this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.
Market Dynamics
Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.
For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.
Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period
For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.
Key features of the study
• This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global calcium channel blocker drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market
Market Segmentation
• Global Calcium Channel Blocker Drugs Market, By Drug Class
o Benzothizepine
o Dihydropyridine
o Phenylalkylamine
• Global Calcium channel blocker drugs market, By Disease Indication
o Hypertension
o Chest Pain
o Arrhythmias
o Others (Blood vessel conditions, Coronary Artery Disease etc.)
• Global Calcium Channel Blocker Drugs Market, By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• Global Calcium Channel Blocker Drugs Market, By Region
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Key Players
o Bausch Health
o Mylan N.V.
o Teva Pharmaceutical Industries Ltd
o Lupin
o Arbor Pharmaceuticals
o GlaxoSmithKline Plc
o Biopharma
o Sofgen Pharmaceuticals
o Glenmark Pharmaceuticals Inc.
o Amneal Pharmaceuticals
o Sun Pharmaceutical Industries Ltd
o Novartis AG
o Zydus Cadila
o Pfizer Inc
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Drivers
o Restraints
o Opportunities
o Impact Analysis
o Key Development Strategies
o Mergers And Acquisition Scenario
o Market Trends
o Brand Analysis
o Regulatory Scenario
o PEST Analysis
o Pricing Analysis
4. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2026 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026–2033
Segment Trends
o Benzothizepine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Dihydropyridine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Phenylalkylamine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
5. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2026 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026–2033
Segment Trends
o Hypertension
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Chest Pain
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Arrhythmias
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Others (Blood vessel conditions, coronary artery disease etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
6. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2026 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026–2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Mn)
7. Global Calcium Channel Blocker Drugs Market, By Region, 2026 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2026–2033
o North America
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Market Size and Forecast, By Drug Class, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Disease Indication, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026 – 2033, (USD Mn)
Market Size and Forecast, By Region/Country, 2026 – 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Competitive Snapshot
Bausch Health
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Mylan N.V.
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Lupin
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Arbor Pharmaceuticals
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
GlaxoSmithKline Plc
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Biopharma
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sofgen Pharmaceuticals
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Glenmark Pharmaceuticals Inc
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Amneal Pharmaceuticals
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sun Pharmaceutical Industries Ltd,
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Novartis AG
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Zydus Cadila
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Pfizer Inc,
o Company Overview
o Disease Indication Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
9. Section
o References
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們